Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:CALTNASDAQ:GPCRNASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.18-0.6%$7.97$5.15▼$10.67$1.11B1.151.34 million shs942,470 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AGPCRStructure Therapeutics$21.68-2.4%$22.64$13.22▼$52.14$1.24B-1.87855,332 shs669,777 shsOLMAOlema Pharmaceuticals$4.17+2.7%$4.58$2.86▼$16.62$285.32M1.99818,819 shs942,448 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-0.61%-0.12%+4.20%+0.25%+50.09%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+2.07%GPCRStructure Therapeutics-2.43%+2.60%-8.98%+2.99%-58.31%OLMAOlema Pharmaceuticals+2.71%-6.50%-7.33%-5.44%-67.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals3.3007 of 5 stars3.52.00.00.04.10.81.9CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AGPCRStructure Therapeutics2.4539 of 5 stars3.52.00.00.02.81.70.6OLMAOlema Pharmaceuticals2.1165 of 5 stars3.51.00.00.01.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5040.59% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AGPCRStructure Therapeutics 3.00Buy$76.50252.86% UpsideOLMAOlema Pharmaceuticals 3.00Buy$24.50487.53% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, CALT, GPCR, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025OLMAOlema PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.005/14/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.005/12/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $75.005/2/2025GPCRStructure TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.004/28/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/22/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/28/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $28.003/19/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $25.003/19/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$247.30M4.47N/AN/A$2.63 per share3.11CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74GPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.28N/A14.61N/A-10.23%-4.41%-3.07%7/30/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AGPCRStructure Therapeutics-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%8/6/2025 (Estimated)OLMAOlema Pharmaceuticals-$96.65M-$2.01N/AN/AN/AN/A-53.56%-47.86%8/5/2025 (Estimated)Latest OLMA, CALT, GPCR, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OLMAOlema Pharmaceuticals-$0.49-$0.36+$0.13-$0.36N/AN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A3/18/2025Q4 2024OLMAOlema Pharmaceuticals-$0.63-$0.51+$0.12-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11CALTCalliditas Therapeutics AB (publ)9.442.692.59GPCRStructure TherapeuticsN/A27.6327.63OLMAOlema PharmaceuticalsN/A7.107.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%CALTCalliditas Therapeutics AB (publ)2.83%GPCRStructure Therapeutics91.78%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%CALTCalliditas Therapeutics AB (publ)2.20%GPCRStructure Therapeutics9.43%OLMAOlema Pharmaceuticals16.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million137.02 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableOLMAOlema Pharmaceuticals7068.42 million46.18 millionOptionableOLMA, CALT, GPCR, and AUPH HeadlinesRecent News About These CompaniesQ2 EPS Estimate for Olema Pharmaceuticals Reduced by AnalystJune 6, 2025 | americanbankingnews.comQ2 EPS Forecast for Olema Pharmaceuticals Cut by AnalystJune 4, 2025 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Wellington Management Group LLPJune 3, 2025 | marketbeat.comH.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials AdvanceMay 30, 2025 | msn.comOlema Pharmaceuticals Selects 90 mg Palazestrant Dose for Phase 3 OPERA-01 and OPERA-02 TrialsMay 29, 2025 | nasdaq.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Millennium Management LLCMay 29, 2025 | marketbeat.comBank of America Corp DE Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 29, 2025 | marketbeat.comOlema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual MeetingMay 28, 2025 | globenewswire.comBNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 23, 2025 | marketbeat.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 21, 2025 | globenewswire.comWall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?May 21, 2025 | zacks.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Buys 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 16, 2025 | marketbeat.comLightspeed Management Company L.L.C. Makes New Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 14, 2025 | marketbeat.comOlema Oncology Reports First Quarter 2025 Financial and Operating ResultsMay 13, 2025 | globenewswire.comWhat Role Might (NASDAQ:OLMA) Play in the Changing Landscape of the...May 12, 2025 | kalkinemedia.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 9, 2025 | globenewswire.comWhy Olema Pharmaceuticals, Inc.’s (OLMA) Stock Is Down 5.94%May 6, 2025 | aaii.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)April 30, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOLMA, CALT, GPCR, and AUPH Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.18 -0.05 (-0.61%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.14 -0.04 (-0.55%) As of 06/13/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 06/12/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Structure Therapeutics NASDAQ:GPCR$21.68 -0.54 (-2.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$21.70 +0.02 (+0.07%) As of 06/13/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Olema Pharmaceuticals NASDAQ:OLMA$4.17 +0.11 (+2.71%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.12 -0.04 (-1.08%) As of 06/13/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
